Within the standard therapy group, the researchers discovered that patients who had a high tumor burden or elevated levels of the enzyme lactate dehydrogenase had shorter event-free survival.

They did, indeed, have higher initial levels of lactate dehydrogenase, an enzyme associated with tissue breakdown, so this possibility should not be discounted.